NTGN Neon Therapeutics Inc.

2.45
-0.09  -4%
Previous Close 2.54
Open 2.54
Price To Book 1.12
Market Cap 69,533,680
Shares 28,381,094
Volume 130,938
Short Ratio
Av. Daily Volume 666,023

NewsSee all news

  1. Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens

    Proprietary class II prediction tool achieved up to a 61-fold improvement in predicting MHC class II peptides compared to standard methods Proprietary capabilities to be integrated into Neon's RECON® bioinformatics

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b data due 3Q 2020.
NEO-PV-01 + Keytruda - NT-002
Non-small Cell Lung Cancer (NSCLC)
Phase 1b top-line data released July 15, 2019. NSCLC - median PFS 5.6 months; melanoma - median PFS not yet reached. Data to be presented 2H 2019.
NEO-PV-01 + nivolumab NT-001
Melanoma, Lung Cancer or Bladder Cancer
Phase 1b data due 2H 2020.
NEO-PV-01 and nivolumab - NT-003
Melanoma

Latest News

  1. Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens

    Proprietary class II prediction tool achieved up to a 61-fold improvement in predicting MHC class II peptides compared to standard methods Proprietary capabilities to be integrated into Neon's RECON® bioinformatics